

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. <b>71247-0065</b>	SERIAL NO. <b>10/591,465</b>
LIST OF REFERENCES CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT <b>Pascal Perriat et al.</b>	
		FILING DATE <b>06/29/2007</b>	GROUP ART UNIT <b>1641</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
/P.D./	1.	2877571	05/12/2006	FR					X
/P.D./	2.	2004/112590	12/29/2004	WO			X		
/P.D./	3.	2005/088314	09/22/2005	WO					X
/P.D./	4.	2005/120590	12/22/2005	WO					X
/P.D./	5.	2867180	09/09/2005	FR					X
/P.D./	6.	2006/012201	02/02/2006	WO			X		
/P.D./	7.	03/080743	10/02/2003	WO			X		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/P.D./	8.	F. HU et al., "Pm-149 DOTA bombesin analogs for potential radiotherapy <i>In vivo</i> comparison with Sm-153 and Lu-177 labeled DO3A-amide-Bala-BBN(7-14)NH <sub>2</sub> ", Nuclear Medicine and Biology 29 (2002) 423-430
/P.D./	9.	W. LI et al., "Development of an in vitro model for assessing the in vivo stability of lanthanide chelates", Nuclear Medicine and Biology 28 (2001) 145-154
/P.D./	10.	H. MATSUDAIRA et al., "Iodine Contrast Medium Sensitizes Cultured Mammalian Cells to X Rays but not to y Rays", Radiation Research 84, 144-148 (1980)
EXAMINER  /Pensee Do/		DATE CONSIDERED  02/27/2012
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. <b>71247-0065</b>	SERIAL NO. <b>10/591,465</b>
LIST OF REFERENCES CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT <b>Pascal Perriat et al.</b>	
		FILING DATE <b>06/29/2007</b>	GROUP ART UNIT <b>1641</b>

## OTHER REFERENCES - continued (Including Author, Title, Date, Pertinent Pages, Etc.)

/P.D./	11.	I. DAS et al., "Backscatter dose perturbation in kilovoltage photon beams at high atomic number interfaces <sup>a)</sup> ", Med. Phys. 22 (6), June 1995, 767-773
/P.D./	12.	C. DIONET et al., "Comparisons of Carboplatin and Cisplatin as Potentiators of 5-Flourouracil and Radiotherapy in the Mouse L1210 Leukaemia Model", Anticancer Research 22: 721-726 (2002)
/P.D./	13.	S. IVY et al., "Clinical Trials With Gadolinium-Texaphyrin and Lutetium-Texaphyrin", Oncology, may 1999, 671-676
/P.D./	14.	D. HEROLDS et al., "Gold microspheres: a selective technique for producing biologically effective dose enhancement", Int. J. Radiat. Biol. 2000, Vol. 76, No. 10, 1357-1364
/P.D./	15.	S. CHO, "Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo study", Phys. Med. Biol. 50 (2005) N163-N173
/P.D./	16.	M. ENGSTROEM et al., "High proton relaxivity for gadolinium oxide nanoparticles" Magn. Reson. Mater. Phy. (2006) 19: 180-186
/P.D./	17.	J. BRIDOT et al., "Hybrid Gadolinium Oxide Nanoparticles: Multimodal Contrast Agents for in Vivo Imaging", J. Am. Chem. Soc. 2007, 129, 5076-5084
/P.D./	18.	M. FLORES-GONZALEZ et al., "Preparing nanometer scaled Tb-doped Y <sub>2</sub> O <sub>3</sub> luminescent powders by the polyol method", Journal of Solid State Chemistry 178 (2005)989-997
/P.D./	19.	C. LOUIS et al., "Synthesis and characterization of Gd <sub>2</sub> O <sub>3</sub> :Eu <sup>3+</sup> phosphor nanoparticles by a sol-lyophilization technique", Journal of Solid State Chemistry 173 (2003)335-341
/P.D./	20.	W. STOEBER et al., "Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range <sup>1</sup> ", Journal of Colloid and Interface Science 26, 62-69 (1968)
/P.D./	21.	P. DEBOUTTIÈRE et al., "Design of Gold Nanoparticles for Magnetic Resonance Imaging", Adv. Funct. Mater. 2006, 16, 2330-2339

EXAMINER

/Pensee Do/

DATE CONSIDERED

02/27/2012

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.